已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for PIK3CA-Mutated, Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced or Metastatic Breast Cancer

医学 帕博西利布 耐受性 内科学 来曲唑 富维斯特朗 肿瘤科 不利影响 转移性乳腺癌 乳腺癌 癌症 三苯氧胺
作者
Komal Jhaveri,Melissa Accordino,Philippe L. Bédard,Andrés Cervantes,Valentina Gambardella,Erika Hamilton,Antoîne Italiano,Kevin Kalinsky,Ian E. Krop,Mafalda Oliveira,Peter Schmid,Cristina Saura,Nicholas C. Turner,Andréa Varga,Sravanthi Cheeti,Stephanie Hilz,Katherine E. Hutchinson,Yanling Jin,Stephanie Royer‐Joo,Ubong Peters
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:42 (33): 3947-3956 被引量:14
标识
DOI:10.1200/jco.24.00110
摘要

PURPOSE To investigate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of inavolisib, a potent and selective small-molecule inhibitor of p110α that promotes the degradation of mutated p110α, in combination with palbociclib and endocrine therapy (ET), in a phase I/Ib study in patients with PIK3CA -mutated, hormone receptor–positive/human epidermal growth factor receptor 2–negative locally advanced/metastatic breast cancer (ClinicalTrials.gov identifier: NCT03006172 ). METHODS Women ≥18 years of age received inavolisib, palbociclib, and letrozole (Inavo + Palbo + Letro arm) or fulvestrant (Inavo + Palbo + Fulv arm) until unacceptable toxicity or disease progression. The primary objective was to evaluate safety or tolerability. RESULTS Fifty-three patients were included, 33 in the Inavo + Palbo + Letro arm and 20 in the Inavo + Palbo + Fulv arm. Median duration of inavolisib treatment was 15.7 and 20.8 months (cutoff: March 27, 2023), respectively. Treatment-related adverse events (TRAEs) occurred in all patients; the most frequent were stomatitis, hyperglycemia, and diarrhea; grade ≥3 any TRAE rates were 87.9% and 85.0%; 6.1% and 10.0% discontinued any treatment due to TRAEs in the Inavo + Palbo + Letro and Inavo + Palbo + Fulv arms, respectively. No PK drug–drug interactions (DDIs) were observed among the study treatments when administered. Confirmed objective response rates were 52.0% and 40.0% in patients with measurable disease, and median progression-free survival was 23.3 and 35.0 months in the Inavo + Palbo + Letro and Inavo + Palbo + Fulv arms, respectively. Available paired pre- and on-treatment tumor tissue and circulating tumor DNA analyses confirmed the effects of study treatment on pharmacodynamic and pathophysiologic biomarkers of response. CONCLUSION Inavolisib plus palbociclib and ET demonstrated a manageable safety profile, lack of DDIs, and promising preliminary antitumor activity.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
哈哈完成签到 ,获得积分10
3秒前
5秒前
6秒前
土豪的行云完成签到,获得积分10
7秒前
9秒前
9秒前
relink完成签到,获得积分10
10秒前
les3发布了新的文献求助10
14秒前
李健的小迷弟应助hyr采纳,获得10
16秒前
萧水白发布了新的文献求助100
16秒前
17秒前
mue完成签到,获得积分10
18秒前
思源应助蔡6705采纳,获得10
20秒前
21秒前
22秒前
25秒前
26秒前
27秒前
大巧不工发布了新的文献求助10
27秒前
今后应助外汇交易员采纳,获得10
28秒前
28秒前
hyr发布了新的文献求助10
28秒前
29秒前
科研通AI2S应助科研通管家采纳,获得10
30秒前
香蕉觅云应助科研通管家采纳,获得10
30秒前
地表飞猪应助科研通管家采纳,获得10
30秒前
30秒前
iNk应助科研通管家采纳,获得20
30秒前
llp发布了新的文献求助20
32秒前
蔡6705发布了新的文献求助10
32秒前
量子星尘发布了新的文献求助10
33秒前
深情安青应助zihangzeng采纳,获得10
34秒前
繁荣的代秋完成签到 ,获得积分10
36秒前
烂漫向卉完成签到,获得积分10
38秒前
39秒前
外汇交易员完成签到,获得积分10
39秒前
40秒前
41秒前
43秒前
44秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3976531
求助须知:如何正确求助?哪些是违规求助? 3520603
关于积分的说明 11204100
捐赠科研通 3257210
什么是DOI,文献DOI怎么找? 1798648
邀请新用户注册赠送积分活动 877835
科研通“疑难数据库(出版商)”最低求助积分说明 806570